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Lower urinary tract symptoms are common in the ageing
population and havemany causes.1 Inmen the various symptoms
are still often attributed to benign prostatic hyperplasia, whatever
their true cause2 and despite the remarks repeatedly made about
nomenclature.3 Recently published guidelines and reviews on
the evaluation and treatment of men with lower urinary tract
symptoms rate four categories of drugs as efficacious: α
blockers, 5-α reductase inhibitors, anticholinergics, and
phosphodiesterase-5 inhibitors. 1 2 4 5
We are surprised at how highly these drugs are recommended
given how well they work. While treatment effects are reported
as being significantly better than those of placebo, we wonder
whether the small differences in patient-reported symptom
scores are perceptible to patients.
Most drugs used for these symptoms were investigated using
the International Prostate Symptom Score (IPSS), equivalent
to the American Urologic Association (AUA) Symptom Index.
This index has seven questions and yields scores ranging from
0 to 35, with higher scores indicating more severe symptoms.
About 20 years ago, Barry and colleagues estimated the smallest
perceptible change in the AUA symptom index in 1222 men
participating in randomised controlled trials investigating
treatment for benign prostatic hyperplasia.6 Patients considered
a 3 point fall in symptom score a “slight” improvement (table⇓),
and since then a 3 point change in score has been regarded as
clinically relevant when assessing treatments. This cut-off has
never been challenged.
What matters to patients
From the patient’s viewpoint, it seems highly arguable that a
slight improvement should be regarded as clinically relevant.
Who would willingly take any drug that carries the risk of (more
or less) severe side effects and drug interactions,7 for only a
slight improvement in symptoms? In nearly all randomised trials
of drugs for lower urinary tract symptoms, changes in different
treatment arms are presented as mean scores. In most cases, the
differences between active and placebo treatments are reported
as “statistically significant,” but we doubt this usually reflects
a clinically relevant change.We found that a difference of more
than 3 points was reported in only four out of 28 studies.8-33 In
these studies the mean decrease in the IPSS score was 6.8
(tamsulosin v placebo),8 3.1 (doxazosin and finasteride v placebo,
but in combination not better than doxazosin monotherapy),9
3.9 (terazosin v placebo),10 and 3.1 (terazosin and finasteride v
placebo, but in combination not better than terazosin
monotherapy).11 Therefore, hardly any of the available drugs is
better than placebo at a “clinically relevant” level. At best, there
is less than a “slight” difference in favour of active treatment.
Because published studies report mean scores, some participants
will have had larger improvements. However, from all available
data it remains unclear how many participants taking active
medication would have experienced moderate or substantial
improvement in symptoms. Such information is essential to
provide patients with reliable information about treatment.
Another study examined the effects on symptomworsening and
complication rates over four years. Even in the high risk patients
included in this trial, the complication rate was low. As a
consequence, the numbers needed to treat derived from this trial
were very high.12
There is an urgent need to publish data on the efficacy of drugs
prescribed for lower urinary tract symptoms, in particular on
the chances of achieving a clinically relevant change.We believe
that a “moderate” (5 points) or “marked” (9 points) improvement
(as defined by Barry and colleagues) should be used to define
clinically relevant change, and meta-analyses of large
randomised trials using this cut-off should be performed. We
encourage authors and drug companies to make their data
available for such analysis. In addition, future studies testing
new treatments could use this cut-off in power analyses. This
would enable physicians to provide better treatment and advice
for the increasing number of men who consult them for lower
urinary tract symptoms.
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Table
Table 1| Relation between mean absolute change in American Urologic Association symptom index (range 0 to 35) and patients’ 13 week
global assessment of change





* Change between baseline and follow-up assessment in 1222 men participating in randomised controlled trials (derived from Barry et al6).
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